论文部分内容阅读
目的:探讨替米沙坦联合硝苯地平缓释片治疗原发性高血压的疗效。方法:选择2013年1月-2014年2月在本院接受治疗的原发性高血压患者120例为研究对象,结合患者入院时间先后分为两组各60例。对照组给予硝苯地平缓释片单独治疗,观察组则给予替米沙坦联合硝苯地平缓释片联合治疗,对比两组患者治疗效果与不良反应发生率的差异,同时比较两组患者治疗前后舒张压、收缩压的差异。结果:观察组患者治疗有效率96.7%,对照组患者治疗有效率85.0%,差异具有统计学意义(P<0.05)。观察患者治疗前血压指标与对照组相比,差异无统计学意义(P>0.05),而观察组患者治疗后收缩压、舒张压均小于对照组,差异具有统计学意义(P<0.05)。两组患者不良反应发生率对比,差异无统计学意义(P>0.05)。结论:替米沙坦联合硝苯地平缓释片治疗原发性高血压患者,相较于单独硝苯地平缓释片有更好的临床效果,患者血压指标改善幅度更高。
Objective: To investigate the curative effect of telmisartan and nifedipine sustained-release tablets in treating essential hypertension. Methods: From January 2013 to February 2014, 120 patients with essential hypertension treated in our hospital from January 2013 to February 2014 were enrolled in this study. Patients were divided into two groups of 60 patients on admission time. The control group was given nifedipine sustained-release tablets alone, while the observation group was treated with telmisartan combined with nifedipine sustained-release tablets. The difference between the two groups was compared with the incidence of adverse reactions. At the same time, the two groups were compared Before and after diastolic blood pressure, systolic blood pressure differences. Results: The effective rate of treatment was 96.7% in observation group and 85.0% in control group, the difference was statistically significant (P <0.05). Compared with the control group, there was no significant difference in blood pressure before treatment between the two groups (P> 0.05). The systolic and diastolic blood pressure in the observation group was lower than that in the control group (P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions (P> 0.05). Conclusion: Telmisartan combined with nifedipine sustained-release tablets in patients with essential hypertension, compared with the single nifedipine sustained-release tablets have better clinical results, patients with higher levels of improvement in blood pressure.